{"download_date": ["ClinicalTrials.gov processed this data on May 09, 2023"], "link_text": ["Link to the current ClinicalTrials.gov record."], "url": ["https://clinicaltrials.gov/show/NCT00739882"], "org_study_id": [27808.0], "nct_id": ["NCT00739882"], "brief_title": ["TRUST Study: Raptiva \u00ae in Hand & Foot Psoriasis"], "acronym": ["TRUST"], "official_title": ["A Phase IV Multicentre, Randomised, Double-blind, Placebo Controlled, Trial to Evaluate the Safety and Efficacy of Raptiva \u00ae in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Involving Hands and/or Feet, With or Without Pustules."], "lead_sponsor": [], "source": ["Merck KGaA, Darmstadt, Germany"], "textblock": ["To evaluate the safety and efficacy of Raptiva \u00ae compared with placebo to control chronic\r\n      moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's\r\n      Global Assessment (PGA - H&F) greater-than or equal to 3 in subjects not suitable for other\r\n      systemic therapies including cyclosporine, methotrexate, and Psoralen-Ultraviolet Light A\r\n      (PUVA)."], "overall_status": ["Terminated"], "why_stopped": ["The study was terminated after the European Medicines Agency recommended to suspend the\r\n    marketing authorisation of Raptiva in the European Union"], "start_date": ["April 2008"], "type": ["Actual", "Actual", "Actual", "Estimate", "Estimate", "Estimate"], "completion_date": ["June 2009"], "primary_completion_date": ["June 2009"], "phase": ["Phase 4"], "study_type": ["Interventional"], "has_expanded_access": ["No"], "allocation": ["Randomized"], "intervention_model": ["Parallel Assignment"], "primary_purpose": ["Treatment"], "masking": ["Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)"], "measure": ["Proportion Of Participants Achieving A Physician's Global Assessment - Hand & Foot (PGA - H&F) Rating Of Clear, Almost Clear Or Mild At Week 12", "Proportion Of Participants Achieving A Physician's Global Assessment - Hand & Foot (PGA - H&F) Rating Of Clear, Or Almost Clear At Week 12", "Proportion Of Participants Achieving A Physician's Global Assessment - Hand & Foot (PGA - H&F) Rating Of Clear, Almost Clear Or Mild At Week 24", "Proportion of Participants From the Initial Placebo Group Achieving a PGA - H&F of Rating of Clear, Almost Clear, or Mild From Week 12 to Week 24.", "Proportion Of Participants Achieving A Physician's Global Assessment (PGA) Rating of Good, Excellent, Or Cleared At Week 12", "Proportion Of Participants Achieving A Physician's Global Assessment (PGA) Rating of Excellent, Or Cleared At Week 12"], "time_frame": ["12 weeks", "12 weeks", "24 weeks", "24 weeks", "12 weeks", "12 weeks"], "description": ["The proportion of subjects achieving a PGA - H&F rating of clear, almost clear, or mild at Week 12:\r\nClear - No signs of plaque psoriasis on the hands and/or feet; Almost Clear - Just perceptible erythema and just perceptible scaling on the hands and/or feet; Mild - Light pink erythema with minimal scaling and with or without pustules on the hands and/or feet", "The proportion of participants achieving a PGA - H&F rating of clear, or almost clear, at Week 12:\r\nClear - No signs of plaque psoriasis on the hands and/or feet; Almost Clear - Just perceptible erythema and just perceptible scaling on the hands and/or feet", "The proportion of participants achieving a PGA - H&F rating of clear, almost clear, or mild at Week 24:\r\nClear - No signs of plaque psoriasis on the hands and/or feet; Almost Clear - Just perceptible erythema and just perceptible scaling on the hands and/or feet; Mild - Light pink erythema with minimal scaling and with or without pustules on the hands and/or feet", "The proportion of participants achieving a PGA - H&F rating of clear, or almost clear, at Week 24:\r\nClear - No signs of plaque psoriasis on the hands and/or feet; Almost Clear - Just perceptible erythema and just perceptible scaling on the hands and/or feet; Mild - Light pink erythema with minimal scaling and with or without pustules on the hands and/or feet", "The proportion of participants achieving a PGA rating of good, excellent, or cleared at Week 12.\r\nCleared = 100% improvement; Excellent = 75-99% improvement; Good = 50-74% improvement", "The proportion of participants achieving a PGA rating of excellent, or cleared at Week 12.\r\nCleared = 100% improvement; Excellent = 75-99% improvement", "Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva \u00ae group with \u2265 50% of improvement will be allocated to extended treatment with Raptiva \u00ae for 12 additional weeks while non-responders to Raptiva \u00ae (improvement \u2264 50%) will be followed in an observational manner for 12 additional weeks without treatment.", "Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)"], "number_of_arms": [2.0], "enrollment": [76.0], "condition": ["Chronic Plaque Psoriasis"], "arm_group_label": ["Efalizumab", "Placebo", "Efalizumab", "Placebo"], "arm_group_type": ["Active Comparator", "Placebo Comparator"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Efalizumab - anti CD11a recombinant human monoclonal antibody", "Placebo"], "criteria": [], "gender": ["All"], "minimum_age": ["18 Years"], "maximum_age": [], "healthy_volunteers": ["No"], "last_name": ["Nicole Selenko-Gebauer, MD"], "role": ["Study Director"], "affiliation": ["Merck Serono S.A., Geneva"], "facility": [], "country": ["Austria"], "verification_date": ["January 2014"], "study_first_submitted": ["August 20, 2008"], "study_first_submitted_qc": ["August 21, 2008"], "study_first_posted": ["August 22, 2008"], "results_first_submitted": ["June 28, 2010"], "results_first_submitted_qc": ["August 4, 2010"], "results_first_posted": ["August 30, 2010"], "last_update_submitted": ["January 26, 2014"], "last_update_submitted_qc": ["January 26, 2014"], "last_update_posted": ["February 27, 2014"], "responsible_party_type": ["Sponsor"], "keyword": ["Efalizumab,", "Chronic plaque psoriasis", "moderate to severe", "involving", "hands", "feet"], "mesh_term": ["Psoriasis", "Antibodies, Monoclonal"], "participant_flow": [], "baseline": [], "outcome_list": [], "reported_events": [], "certain_agreements": [], "limitations_and_caveats": ["Following the recommendation of the European Medicines Agency (EMEA) to suspend the marketing authorization of Raptiva\u00ae and the subsequent premature termination of this trial analysis of efficacy-related endpoints was not performed"], "point_of_contact": []}